Compare Gilead Sciences, Inc. (GILD) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Altria Group Inc — how do they compare? Gilead Sciences, Inc. trades at $150.99 (market cap $182.40B), while Altria Group Inc trades at $71.77 (market cap $119.25B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Altria Group Inc pays the higher dividend (6.22%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Altria Group Inc for 154 Days on average.
| GILD | MO | |
|---|---|---|
Market Cap | $182.40B | $119.25B |
Volume | 4,469,821 | 11,178,169 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $74.92 |
52-Week Low | $116.74 | $54.72 |
Typical Hold Time | 111 Days | 154 Days |
Enterprise Value | $205.46B | $141.46B |
Dividend Yield | 2.23% | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Altria Group (MO) trades at $71.89, up 3.61% with a bullish technical signal from moving averages. The company maintains strong profitability with 39% net margins and generates robust operating cash flow of $9.29B, supporting its 6.6% dividend yield. Recent earnings show mixed results with one beat and two misses in the last four quarters. The stock trades below analyst consensus target of $69.71 despite negative shareholder equity of -$2.24B due to high debt levels.
MO offers income investors an attractive dividend yield but faces structural challenges including declining cigarette volumes and regulatory uncertainty. Analyst consensus remains positive with 61.5% buy ratings, though concerns persist about the sustainability of dividend payments given the company's negative equity position and competitive pressures in smoke-free alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
